{"id":60565,"date":"2024-02-28T06:55:40","date_gmt":"2024-02-28T06:55:40","guid":{"rendered":"https:\/\/medsname.com\/rosuline\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rosuline","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nb\/product\/rosuline\/","title":{"rendered":"Rosuline"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Rosuline?<\/h3>\n<p style=\"margin:0;\"><strong>Rosuline<\/strong> er en <strong>5 \/ 10 mg rosuvastatin tablet<\/strong> from Torrent Pharma &mdash; a high-intensity HMG-CoA reductase inhibitor (statin), hydrophilic. Statins reduce cardiovascular events by <strong>20-30% per mmol\/L LDL-kolesterolreduksjon<\/strong> across primary prevention, secondary prevention, diabetes, and post-stroke populations. Rosuvastatin was introduced by AstraZeneca in 2003 as <strong>Crestor<\/strong>. Hydrophilic statin; primarily excreted unchanged in faeces (10% renal, 90% biliary); minimal CYP metabolism (mostly CYP2C9 modestly). Dose range 5-40 mg once daily; 20-40 mg are high-intensity. Potency: rosuvastatin 20 mg reduces LDL-C by 52%; 40 mg by 55% &mdash; the most potent statin per mg. Typical dose: once daily, evening (for short-half-life statins) or any time for rosuvastatin (half-life long enough that timing does not matter). Main side effects: muscle symptoms (0.1-1% with confirmed CK elevation; up to 10% nocebo muscle aches), mild transaminase elevation (3%), new-onset diabetes in at-risk patients (~0.2 per 100 patient-years). Absolutely contraindicated in pregnancy, active liver disease, rhabdomyolysis history.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Hva du f\u00e5r med MedsBase:<\/strong> WHO-GMP-sertifisert produsent \u00b7 Diskret emballasje \u00b7 Verdensomspennende levering \u00b7 1 400+ verifiserte <a href=\"https:\/\/medsbase.com\/nb\/reviews\/\">kundeanmeldelser<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Hver ordre er dekket av v\u00e5r <a href=\"https:\/\/medsbase.com\/nb\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n<h3>Hvorfor bestille fra MedsBase<\/h3>\n<p>V\u00e5re generiske legemidler kommer fra WHO-GMP-sertifiserte produsenter og sendes over hele verden i diskret, n\u00f8ytral emballasje \u2014 ingen legemiddelnavn p\u00e5 utsiden av pakken. Kortbetalinger h\u00e5ndteres av en regulert betalingsbehandler (kontoutskrifter viser en regulert kortbetalingsprosessor \u2014 aldri \u201cMedsBase\u201d eller noe legemiddelnavn). Krypto og SEPA bankoverf\u00f8rsel godtas ogs\u00e5. Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy.<\/p>\n<h2 class=\"wp-block-heading\">What Is Rosuline?<\/h2>\n<p>Rosuline is an oral 5 \/ 10 mg rosuvastatin tablet from Torrent Pharma, supplied in 30-180 tablets. Rosuvastatin was introduced by AstraZeneca in 2003 as <strong>Crestor<\/strong>. Hydrophilic statin; primarily excreted unchanged in faeces (10% renal, 90% biliary); minimal CYP metabolism (mostly CYP2C9 modestly). Dose range 5-40 mg once daily; 20-40 mg are high-intensity.<\/p>\n<h2 class=\"wp-block-heading\">How Rosuvastatin Works<\/h2>\n<p>Rosuvastatin inhibits <strong>HMG-CoA-reduktase<\/strong>, det hastighetsbegrensende enzymet for leverens kolesterolsyntese. Nedstr\u00f8ms:<\/p>\n<ul>\n<li><strong>Redusert intracellul\u00e6rt kolesterol i hepatocytter<\/strong> \u2014 utl\u00f8ser sterol-regulatorisk element-bindende protein (SREBP) aktivering og oppregulering av LDL-reseptorekspresjon p\u00e5 hepatocyttoverflaten<\/li>\n<li><strong>\u00d8kt klaring av sirkulerende LDL-C<\/strong> \u2014 den prim\u00e6re mekanismen for LDL-senkning<\/li>\n<li><strong>Modest reduksjon av triglyserider<\/strong> (10-20%) og moderat \u00f8kning i HDL (5-10%)<\/li>\n<li><strong>Pleiotrope effekter<\/strong> utover LDL-senkning \u2014 redusert vaskul\u00e6r inflammasjon (hs-CRP nedgang), forbedret endotelfunksjon, stabilisering av plakk, redusert plateletreaktivitet. Omfanget av den kliniske fordelen i studiene overg\u00e5r det som kan forklares av LDL-C-endring alene.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Rosuline Dosage<\/h2>\n<p><strong>Prim\u00e6rforebygging (ingen tidligere CV-hendelse):<\/strong> start 5-10 mg once daily; titrate to target based on 10-year ASCVD risk. For diabetics or ASCVD risk &gt;7.5%, moderate-intensity (10-20 mg) is typical.<\/p>\n<p><strong>Sekund\u00e6rforebygging (tidligere MI, slag, PAD eller diabetisk CVD):<\/strong> high-intensity therapy &mdash; 20-40 mg once daily. Target LDL-C &lt;1.8 mmol\/L (&lt;70 mg\/dL) per 2019 ESC and &lt;1.4 mmol\/L (&lt;55 mg\/dL) for very-high-risk ASCVD per 2021 ESC update.<\/p>\n<p><strong>Familial hyperkolesterolemi:<\/strong> maximum-tolerated statin (usually 40 mg) often combined with ezetimibe 10 mg and\/or PCSK9 inhibitor (alirocumab\/evolocumab\/inclisiran) to achieve guideline targets.<\/p>\n<p><strong>Administrering:<\/strong> once daily with or without food. Any time of day &mdash; 19-hour half-life means timing does not meaningfully change efficacy.<\/p>\n<p><strong>Overv\u00e5kning:<\/strong><\/p>\n<ul>\n<li><strong>Utgangspunkt:<\/strong> fullt lipidpanel, levertester (ALT), kreatinkinase (CK), HbA1c eller fasteglukose, kreatinin, thyreoideastimulerende hormon (TSH) hvis ikke nylig sjekket.<\/li>\n<li><strong>4-12 uker:<\/strong> repeat lipids to assess response. Expect rosuvastatin 20 mg reduces LDL-C by 52%; 40 mg by 55% &mdash; the most potent statin per mg. Dose-escalate if target not met.<\/li>\n<li><strong>\u00c5rlig:<\/strong> lipider, levertester (med mindre symptomatisk). CK kun ved muskelklager, ikke rutinemessig.<\/li>\n<li><strong>Stopp og unders\u00f8k:<\/strong> CK &gt;10\u00d7 ULN, ALT &gt;3\u00d7 ULN og stigende, vedvarende uforklarlig muskelvondt med CK &gt;5\u00d7 ULN, rabdomyolyse (m\u00f8rk urin, markant svakhet).<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Evidence for Rosuvastatin<\/h2>\n<p><strong>JUPITER (2008)<\/strong> &mdash; rosuvastatin 20 mg in 17,802 patients with normal LDL but elevated hs-CRP reduced CV events by 44%; extended statin indications to &#8220;inflammation-driven&#8221; risk. <strong>ASTEROID (2006)<\/strong> &mdash; 40 mg for 24 months produced measurable coronary plaque regression on IVUS. <strong>SATURN (2011)<\/strong> &mdash; rosuvastatin 40 mg vs atorvastatin 80 mg; rosuvastatin slightly greater LDL reduction but no meaningful regression advantage. <strong>HOPE-3 (2016)<\/strong> &mdash; rosuvastatin 10 mg primary prevention in intermediate-risk patients reduced CV events by 24%.<\/p>\n<h2 class=\"wp-block-heading\">Godkjente og evidensbaserte bruksomr\u00e5der<\/h2>\n<ul>\n<li>Primary and secondary prevention of cardiovascular disease<\/li>\n<li>Inflammation-driven risk with elevated hs-CRP (JUPITER)<\/li>\n<li>Patients who are CYP3A4-interaction-prone (simpler pharmacology than atorvastatin)<\/li>\n<li>Familial hyperkolesterolemi<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Praktiske hensyn<\/h2>\n<p>Fewer CYP3A4 interactions than atorvastatin &mdash; a practical advantage when patients take macrolides, azoles, or certain antiretrovirals. <strong>Dose-capped in Asian patients<\/strong> &mdash; the FDA reduced the Asian starting dose to 5 mg after pharmacokinetic studies showed 2-fold higher plasma levels. <strong>Creatine kinase and LFT monitoring<\/strong> as for all statins.<\/p>\n<h2 class=\"wp-block-heading\">Bivirkninger<\/h2>\n<p><strong>Vanlige (&gt;1%):<\/strong><\/p>\n<ul>\n<li><strong>Myalgi (muskelsmerter)<\/strong> \u2014 plagsomt hos 5-10% av brukerne; bekreftede statinassosierte muskelsymptomer med CK-\u00f8kning hos 0,1-1%. H\u00f8y nocebokomponent: SAMSON-studien (2020) viste ingen forskjell mellom statin og placebo i dobbeltblindede n-of-1-kryssfors\u00f8k hos mange \u201cstatinintolerante\u201d pasienter.<\/li>\n<li><strong>Mild forh\u00f8yelse av transaminaser<\/strong> \u2014 3% har ALT-\u00f8kning under 3\u00d7 ULN; vanligvis midlertidig og krever ikke doseendring.<\/li>\n<li><strong>Nyoppdaget diabetes<\/strong> \u2014 absolutt overrisiko ~0,2 per 100 pasient\u00e5r, hovedsakelig hos pasienter med prediabetes. Hjerte-kar-fordel overg\u00e5r langt diabetesrisiko.<\/li>\n<li><strong>Hodepine, ford\u00f8yelsesbesv\u00e6r, kvalme<\/strong><\/li>\n<li><strong>Erektil dysfunksjon<\/strong> (uvanlig; mekanisme uklar)<\/li>\n<li><strong>S\u00f8vnforstyrrelser, kognitiv t\u00e5ke<\/strong> (rapportert men ikke konsistent i RCT-er)<\/li>\n<\/ul>\n<p><strong>Uvanlig, men klinisk viktig:<\/strong><\/p>\n<ul>\n<li><strong>Rabdomyolyse<\/strong> (10\u00d7 ULN.<\/li>\n<li><strong>Immunmediert nekrotiserende myopati<\/strong> \u2014 sjelden vedvarende myopati som fortsetter etter statinavbrudd; anti-HMGCR-antistoffmediert. Krever immunosuppressiv behandling.<\/li>\n<li><strong>Alvorlig transaminitt \/ legemiddelindusert leverskade<\/strong> \u2014 sjeldent; stopp hvis ALT &gt;3\u00d7 ULN med symptomer eller stigende trend.<\/li>\n<li><strong>Perifer nevropati<\/strong> (sjeldent)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Kontraindikasjoner<\/h2>\n<ul>\n<li><strong>Graviditet og amming<\/strong> \u2014 statiner er kontraindisert; kolesterol er n\u00f8dvendig for fosterets nevroutvikling.<\/li>\n<li><strong>Aktiv leversykdom<\/strong> eller uforklarlig vedvarende ALT &gt;3\u00d7 ULN.<\/li>\n<li><strong>Tidligere rabdomyolyse eller alvorlig statinintoleranse<\/strong> bekreftet i dobbelblind reutfordring.<\/li>\n<li><strong>Samtidig bruk av sterke CYP3A4-hemmere<\/strong> (for rosuvastatin): clarithromycin, itraconazole, ritonavir &mdash; hold statin or switch to rosuvastatin\/pravastatin.<\/li>\n<li>Overf\u00f8lsomhet mot statinet.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Legemiddelinteraksjoner<\/h2>\n<ul>\n<li><strong>CYP2C9 and OATP1B1 transporter interactions<\/strong> &mdash; ciclosporin, gemfibrozil, and some antiretrovirals raise rosuvastatin levels. Dose-cap rosuvastatin at 5 mg with ciclosporin; avoid with gemfibrozil.<\/li>\n<li><strong>Grapefruktjuice<\/strong> &mdash; minimal interaction with rosuvastatin (hydrophilic; minimal CYP3A4 metabolism).<\/li>\n<li><strong>Fibrater (gemfibrozil, fenofibrate)<\/strong> \u2014 \u00f8kt risiko for myopati. Gemfibrozil er den verste; fenofibrat er det foretrukne fibratet for kombinasjon. Reserver kombinasjoner for spesialistbehandling av dyslipidemi.<\/li>\n<li><strong>H\u00f8y dose niacin<\/strong> \u2014 \u00f8kt risiko for myopati. Lav dose niacin (1-2 g) tolereres vanligvis.<\/li>\n<li><strong>Warfarin<\/strong> \u2014 liten \u00f8kning i INR ved start av statin; kontroller INR etter 1 uke. Ikke en kontraindikasjon.<\/li>\n<li><strong>Digoxin<\/strong> \u2014 liten \u00f8kning i digoksinniv\u00e5 med atorvastatin (P-glykoprotein); vanligvis ikke klinisk signifikant.<\/li>\n<li><strong>Alkohol<\/strong> \u2014 h\u00f8yt inntak \u00f8ker risikoen for leverskade. Moderat inntak er akseptabelt.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Oppbevaring<\/h2>\n<p>Store Rosuline below 25&deg;C in the original blister pack. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">Vanlige sp\u00f8rsm\u00e5l<\/h2>\n<h3 class=\"wp-block-heading\">Do I have to take Rosuline at night?<\/h3>\n<p>No &mdash; rosuvastatin has a 19-hour half-life, long enough that the ~24-hour cycle of nocturnal cholesterol synthesis is covered regardless of dose timing. Morning dosing with other medications is fine. The &#8220;take statins at night&#8221; rule comes from short-half-life statins (simvastatin, lovastatin).<\/p>\n<h3 class=\"wp-block-heading\">What if I get muscle aches on Rosuline?<\/h3>\n<p>Vanlig og sjelden farlig. Sjekk kreatinkinase (CK). Hvis CK er normalt, er smertene vanligvis ikke relatert til statiner \u2014 SAMSON-studien (2020) viste at de fleste \u201cstatinintolerante\u201d pasienter hadde like mye smerter p\u00e5 placebo i dobbeltblind crossover. Alternativer: fortsett statin med vitamin D-tilskudd (hvis mangel), pr\u00f8v koenzym Q10 (svakt bevis, men lav risiko), bytt statin (rosuvastatin har lavere forekomst av muskelsymptomer enn simvastatin og atorvastatin i noen studier), reduser dosen, eller bruk annenhver dags dosering. Bare stopp hvis CK &gt;10\u00d7 \u00f8vre normalgrense, symptomene er invalidiserende, eller det er objektiv muskelsvakhet.<\/p>\n<h3 class=\"wp-block-heading\">Will Rosuline give me diabetes?<\/h3>\n<p>Statiner for\u00e5rsaker en liten \u00f8kning i nyoppst\u00e5tt diabetes \u2014 omtrent 1 ekstra diabetes tilfelle per 1 000 personer per \u00e5r, hovedsakelig hos de som allerede har h\u00f8y risiko for diabetes (overvektig, prediabetes, familiehistorie). Den samme behandlingen forhindrer omtrent 5-10 hjerte- og karsykdomstilfeller per 1 000 personer per \u00e5r i de samme populasjonene \u2014 s\u00e5 nettofordelen er klart positiv. Ikke stopp en statin kun p\u00e5 grunn av diabetesrisiko.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Rosuline with grapefruit juice?<\/h3>\n<p>Yes &mdash; rosuvastatin has minimal CYP3A4 metabolism, so the grapefruit interaction is minor. Contrast with atorvastatin where regular grapefruit consumption is discouraged.<\/p>\n<h3 class=\"wp-block-heading\">How long will I need to take Rosuline?<\/h3>\n<p>P\u00e5 ubestemt tid, i nesten alle tilfeller. \u00c5 stoppe en statin f\u00f8rer til at LDL-C \u00f8ker igjen innen noen uker, og kardiovaskul\u00e6r beskyttelse g\u00e5r tapt innen noen m\u00e5neder. Statiner er livslang forebyggende behandling for aterosklerotisk sykdom, ikke en kort kur.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Rosuline in pregnancy?<\/h3>\n<p>Nei \u2014 statiner er kontraindisert under graviditet og amming. Kolesterol er n\u00f8dvendig for fosterets nevroutvikling; statiner passerer placenta. Stopp statinen f\u00f8r planlagt graviditet; hvis graviditeten er uplanlagt, stopp umiddelbart og diskuter risikoene med en spesialist. Pasienter med famili\u00e6r hyperkolesterolemi kan vanligvis trygt utsette statinbehandlingen under graviditet og amming.<\/p>\n<h3 class=\"wp-block-heading\">Where can I buy Rosuline online?<\/h3>\n<p>You can buy Rosuline (rosuvastatin 5 \/ 10 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.<\/p>\n<h2 class=\"wp-block-heading\">Relaterte hjerte- og hypertensjonsmedisiner<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nb\/aldactone\/\">Aldactone \u2014 Spironolakton (ikke-selektiv MR-antagonist)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/amlopres-at\/\">Amlopres AT \u2014 Amlodipin + Atenolol kombinasjon<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/aten\/\">Aten \u2014 Atenolol (betablokker)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/ecosprin\/\">Ecosprin \u2014 Aspirin 75\/150 mg<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/eptus\/\">Eptus \u2014 Eplerenone 25\/50 mg (selektiv MR-antagonist)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/lotensyl\/\">Lotensyl \u2014 Cilnidipin 10\/20 mg (L+N-type CCB)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/high-blood-pressure-medication\/\"><strong>Se alle h\u00f8yt blodtrykksmedikamenter<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Medisinsk ansvarsfraskrivelse.<\/strong> Denne siden er kun til informasjonsform\u00e5l og erstatter ikke medisinsk r\u00e5dgivning fra en kvalifisert helsepersonell. H\u00f8yt blodtrykk, hjertesvikt og arytmier krever diagnose, overv\u00e5kning og dosindividualisering av en lege \u2013 bruk alltid betablokkere under medisinsk veiledning.<\/div>\n<h3 class=\"wp-block-heading\">Hvorfor bestille fra MedsBase<\/h3>\n<p>Rosuline is supplied through a WHO-GMP certified manufacturer with full COA documentation. We ship worldwide in plain, discreet packaging, and every order is covered by our <a href=\"\/nb\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. Din kontoutskrift ved kortbetaling viser den regulerte betalingsbehandleren (en regulert kortbetalingsbehandler), aldri \u201cMedsBase\u201d eller noe medikamentnavn.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Relaterte alternativer<\/h3>\n<p>Andre produkter innen <strong>Kroniske tilstander<\/strong> som kunder ogs\u00e5 ser p\u00e5:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nb\/triohale-inhaler\/\">Triohale Inhalator<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/montair\/\">Montair<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/lomoother\/\">Lomoother<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/unicontin-e\/\">Unicontin-E<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/ventocortil\/\">Ventocortil<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Rosuline is Torrent Pharma&#8217;s rosuvastatin 5\/10 mg tablets \u2014 the most potent statin per mg. Originally AstraZeneca Crestor (2003). Hydrophilic, predominantly biliary clearance, minimal CYP3A4 metabolism \u2014 making it the preferred statin for patients on macrolides, azoles, or antiretrovirals. JUPITER (2008) extended statin indications to normal-LDL, high-hsCRP populations. HOPE-3 (2016) primary prevention in intermediate risk. Asian patients start at 5 mg (pharmacokinetic dose-cap).<\/p>","protected":false},"featured_media":60566,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356,3953],"product_tag":[4882,4637],"class_list":{"0":"post-60565","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-heart-blood-pressure","9":"product_cat-high-blood-pressure-medication","10":"product_cat-high-cholesterol-treatments","11":"product_tag-rosuline","12":"product_tag-rosuvastatin","14":"first","15":"instock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable","19":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product\/60565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/comments?post=60565"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/media\/60566"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/media?parent=60565"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_brand?post=60565"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_cat?post=60565"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_tag?post=60565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}